CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins

Psychopharmacology

Volumn 132, Issue 3, 1997, Pages 227-236

  Smadja, Claire ^a   Ruiz, Fernando ^a   Coric, Pascale ^a   Fournié Zaluski, Marie Claude ^a   Roques, Bernard P ^a   Maldonado, Rafael ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

Anterior nucleus accumbens; Antidepressant like effects; Caudate nucleus; CCK B receptors; Central amygdala; Enkephalin degrading enzymes; PD 134,308; RB 101

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; ANTIDEPRESSANT AGENT; BC 264; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR AGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; ENKEPHALIN; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CAUDATE NUCLEUS; CONDITIONING; CONTROLLED STUDY; DRUG POTENTIATION; ELECTRIC SHOCK; FACILITATION; HISTOLOGY; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIMBIC SYSTEM; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MICROINJECTION; NEUROANATOMY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

AMYGDALA; ANIMALS; CAUDATE NUCLEUS; DISULFIDES; ENKEPHALINS; ENZYME INHIBITORS; HORMONE ANTAGONISTS; INDOLES; INJECTIONS, INTRAVENTRICULAR; LIMBIC SYSTEM; MALE; MEGLUMINE; MICE; MOTOR ACTIVITY; NEPRILYSIN; NUCLEUS ACCUMBENS; PHENYLALANINE; RATS; RATS, WISTAR; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ;

EID: 0030855095     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050340     Document Type: Article

References (77)

1. 1 receptor stimulation. Eur J Pharmacol 216:157-166
2. Belcheva I, Belcheva S, Petkov VV, Petkov VD (1994) Asymmetry in behavioral responses to cholecystokinin microinjected into the rat nucleus accumbens and amygdala. Neuropharmacology 33:995-1002
3. Benolicl JJ, Bourgoin S, Mauborgne A, Legrand JC, Hamon M, Cesselin F (1991) Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opioid agonists, and selective blockade of μ-dependent inhibition by κ receptor stimulation. Neurosci Lett 124:204-207
4. Benoliel JJ, Mauborgne A, Bourgoin S, Legrand JC, Hamon M, Cesselin F (1992) Opioid control of the in vitro release of cholecystokinin-like material from the rat substantia nigra. J Neurochem 58:916-922
5. Bozarth MA (1991) Interactions between endogenous opioids and dopamine: implications for reward and aversion. In: Willner P. Scheel-Kruger J (eds) The mesolimbic dopaminergic system: from motivation to action. Wiley, Chichester, pp 301-330
6. Butcher SP, Varro A, Kelly JS, Dockray GJ (1989) In vivo studies on the enhancement of cholecystokinin release in the rat striatum by dopamine depletion. Brain Res 505:119-122
7. 28,31)- CCK 25-33S. Eur J Neurosci 4:563-573
8. 3H]-(±)-L-364.718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Mol Pharmacol 30:212-217
9. Charpentier B, Durieux C, Pélaprat D, Dor A, Reibaud M, Blanchard JC, Roques BP (1988) Enzyme resistant CCK analogs with high affinities for central receptors. Peptides 9: 835-841
10. 2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases Mu opioid receptors in mouse striatum. Neuroscience 54:669-680
11. Cooper SJ (1991) Interactions between endogenous opioids and dopamine: implications for reward and aversion. In: Willner, P, Scheel-Kruger J (eds) The mesolimbic dopaminergic system: from motivation to action. Wiley, Chichester, pp 331-366
12. Crawley JN (1988) Modulation of mesolimbic dopaminergic behaviors by cholecystokinin. In: Kalivas PD, Nemeroff CB, (eds) The mesolimbic dopaminergic system. Vol. 537, pp 380-396
13. Crawley JN (1992) Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. J Neurosci 12:3380-3391
14. Daugé V, Dor A, Féger J, Roques BP (1989) The behavioural effects of CCK8 injected into the medial accumbens are dependant on the motivational state of the rat. Eur J Pharmacol 163:25-32
15. Daugé V, Derrien M, Blanchard JC, Roques BP (1992) The selective CCK-B agonist BC 264 injected in the antero-lateral part of the nucleus accumbens reduces the spontaneous alternation behaviour of rats. Neuropharmacology 31:67-75
16. Daugé V, Mauborgne A, Cesselin F, Fournié-Zaluski MC, Roques BP (1996) The dual peptidase inhibitor RB 101 induces a long lasting increase in the extracellular level of Mct-enkephalin-like material in the nucleus accumbens of freely moving rats. J Neurochem 67:1301-1308
17. Derrien M, Durieux C, Roques BP (1994a) Antidepressant-like effects of CCK-B antagonists in mice: antagonism by naltrindole. Br J Pharmacol 111:956-960
18. Derrien M, MeCort-Tranchepain I, Ducos B, Roques BP, Durieux C (1994b) Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol Biochem Behav 49:133-141
19. Derrien M, Daugé V, Blommaert A, Roques BP (1994c) The selective CCK-B agonist, BC 264, impairs socially reinforced memory in the three-panel runway test in rats. Behav Brain Res 65: 139-146
20. Di Chiara G, North RA (1992) Neurobiology of opiate abuse. Trends Pharmacol Sci 13:185-193
21. Ding XZ, Bayer BM (1993) Increases of CCK mRNA and peptide in different brain areas following acute and chronic administration of morphine. Brain Res 625:139-144
22. Dockray GJ (1976) Immunochemical evidence of cholecystokinin-like peptides in brain. Nature 264:568-570
23. Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD (1990) The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 176:35-44
24. Durieux C, Charpentier B, Pélaprat D, Roques BP (1986) Investigation on the metabolism of CCK-8 analogues by rat brain slices. Neuropeptides 7:1-9
25. Faris PL, Komisaruk B, Waitkins LR, Mayer DJ (1983) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219:1449-1451
26. Faris PL, McLaughlin CL, Baile CA, Olney JW, Komisaruk BR (1984) Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin. Science 226:1215-1217
27. Fekete M, Lengyel A, Hegedüs B, Penke B, Zarandy M, Toth GK, Telegdy G (1984) Further analysis of the effects of cholecystokinin octapeptides on avoidance behaviour in rats. Eur J Pharmacol 98:79-91
28. Fournié-Zaluski MC, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R, Roques BP (1992) Mixed-inhibitor prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J Med Chem 35:2474-2481
29. Gall C, Lauterborn J, Burks D, Seroogy K (1987) Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res 403:403-408
30. Hernando F, Fuentes JA, Roques BP, Ruiz-Gayo M (1994) The CCK-B receptor antagonist L-365.260 elicits antidepressanttype effects in the forced swim test in mice. Eur J Pharmacol 261:257-263
31. Hernando F, Fuentes JA, Fournié-Zaluski MC, Roques BP, Ruiz-Gayo M (1996) Antidepressant-like effects of CCK-B receptor antagonists: involvement of the opioid system. Eur J Pharmacol 318:221-229
32. Hill DR, Campbell NJ, Shaw TM, Woodruff GN (1987) Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide antagonists. J Neurosci 7:2967-2976
33. Hökfelt T, Rehfeld JF, Skirboll L, Ivemark B, Goldstein M, Markey K (1980) Evidence for coexistence of dopamine and CCK in mesolimbic neurons. Nature 285:476-477
34. Hugues J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87:6728-6732
35. Innis RB, Snyder SH (1980) Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA 77:6917-6921
36. Itoh S, Katsuura G, Maeda Y (1982) Caerulein and cholecystokinin suppress β-endorphin-induced analgesia in the rat. Eur J Pharmacol 80:421-425
37. Josselyn SA, Franco VP, Vaccarino FJ (1996) PD-135158, a CCK-B receptor antagonist, microinjected into the nucleus aecumbens and the expression of conditioned rewarded behavior. Neurosci Lett 209:85-88
38. Kameyama T, Nagasaka M (1982) Effects of apomorphine and diazepam on a quickly learned conditioned suppression in rats. Pharmacol Biochem Behav 17:59-63
39. Kameyama T, Nagasaka M, Yamada K (1985) Effects of antidepressant drugs on a quickly-learned conditioned-suppression response in mice. Neuropharmacology 24:285-290
40. Kiraly I, Van Ree JM (1987) Behavioral evidence for the involvement of endogenous opioids in the interaction between cholecystokinin and brain dopamine systems. Neurosci Lett 74: 343-347
41. Konkoy CS, Davis TP (1995) Regional metabolism of metenkephalin and cholecystokinin on intact rat brain slices: characterization of specific peptidases. J Neurochem 65: 2773-2782
42. Ladurelle N, Keller N, Roques BP, Daugé V (1993) Effects of CCK-8 and of the CCK-B selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats. Brain Res 628:254-262
43. Le Moal M, Simon H (1991) Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev 71: 155-234
44. Maldonado R, Derrien M, Noble F, Roques BP (1993) Association of the peptidase inhibitor and a CCK-B antagonist strongly enhances antinociceptive responses. Neuroreport 4:947-950
45. Mansour A, Fox CA, Akil H, Watson SJ (1995) Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 18:22-29
46. Moran TH, Robinson PH, Goldrich MS, McHugh PR (1986) Two brain cholecystokinin receptors for behavioural actions. Brain Res 362:175-179
47. Mueller K, Whiteside DA (1990) Enkephalin prevents CCK-induced enhancement of amphetamine-induced locomotor stereotypy. Brain Res 513:119-124
48. Nabeshima T, Katoh A, Kameyama T (1988) Inhibition of enkephalin degradation attenuated stress-induced motor suppression (conditioned suppression of motilily). J Pharmacol Exp Ther 244:303-309
49. NIH publication (1985) Guide for the care and use of laboratory animal. NIH. no. 82-85
50. Noble F, Soleilhac JM, Soroca-Lucas E, Turcaud S, Fournié-Zaluski MC, Roques BP (1992) Inhibition of the enkephalin-metabolizing enzymes by the first systematically active mixed inhibitor prodrug RB101 induces potent analgesic responses in mice and rats. J Pharmacol Exp Ther 261:181-190
51. Noble F, Derrien M, Roques BP (1993) Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br J Pharmacol 109:1064-1070
52. Nyberg F, Legreves P, Sundqvist C, Terenius L (1984) Characterization of substance P(1 7) and (1 8) generating enzyme in human cerebrospinal fluid. Biochem Biophys Res Commun 125:244-250
53. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, New York
54. 8. Functional significance of subregional distributions. Neurochem Int 10:495-508
55. Pohl M, Benoliel JJ, Bourgoin S, Lombard MC, Mauborgne A, Taquet H, Carayon A, Besson JM, Cesselin F, Hamon M (1990) Regional distribution of calcitonin gene-related peptide-, substance P, cholecystokinin-, met-enkephalin-, and dynorphin A (1 8)-like materials in the spinal cord and dorsal root ganglia of adult rats: effects of dorsal rhizotomy and neonatal capsaicin. J Neurochem 55:1122-1130
56. Pu SF, Zhuang HX, Han JS (1994) Cholecystokinin octapeptide (CCK-8) antagonizes morphine analgesia in nucleus accumbens of the rat via the CCK-B receptor. Brain Res 657:159-164
57. Rex A, Barth T, Vogt JP, Domeney A, Fink H (1994) Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat model of anxiety. Neurosci Lett 172:139-142
58. 1A agonist, in three stress paradigms immobilization, forced swim test and conditioned fear. Brain Res 580:205-214
59. Roques BP, Daugé V, Gacel G, Fournié-Zaluski MC (1985) Selective agonists and antagonists of delta opioid receptors and inhibitors of enkephalin metabolism. Potential use in treatment of mental illness. In: Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM (eds) Biological psychiatry developments in psychiatry, vol 7. Elsevier, New York, pp 287-289
60. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, Beaumont A (1993) Neutral endopeptidase 24.11: structure, inhibition and experimental and clinical pharmacology. Pharmacol Rev 45: 87-146
61. 3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. J Neurochem 59:1805-1811
62. Saito A, Sankaran H, Goldfine ID, Williams JA (1980) Cholecystokinin receptors in the brain: characterization and distribution. Science 208:1155-1156
63. Sakamoto C, Williams JA, Godfine ID (1984) Brain CCK receptors are structurally distinct from pancreas CCK receptors. Biochem Biophys Res Commun 124:497-502
64. Shippenberg TS, Bals-Kubik R, Hertz A (1993) Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J Pharmacol Exp Ther 265:53-59
65. Smadja C, Maldonado R, Turcaud S, Fournié-Zaluski MC, Roques BP (1995) Opposite role of CCK-A and CCK-B receptors in the modulation of endogenous enkephalin antidepressant-like effects. Psychopharmacology 120:400-408
66. Suh HH, Collins KA, Tseng LF (1992) Intrathecal cholecystokinin octapeptide attenuates the antinociception and release of immunoreactive met-enkephalin induced by intraventricular β-endorphin in the rat. Neuropeptides 21:131-137
67. Tejedor-Real P, Mico JA, Maldonado R, Roques BP, Gibert-Rahola J (1995) Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol Biochem Behav 52:145-152
68. Treit D (1984) Animal model for the study of anti-anxiety agents: a review. Neurosci Biobehav Rev 9:203-222
69. Vaccarino F, Koob GF (1984) Microinjection of nanogram amounts of sulfated cholecystokinin octapeptide into the rat nucleus accumbens attenuates brain stimulation reward Neurosci Lett 52:61-66
70. Valverde O, Maldonado R, Fournié-Zaluski MC, Roques BP (1994) CCK-B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 270: 77-88
71. Watkins LR, Kinscheck IB, Mayor DJ (1985) Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide. Brain Res 327:169-180
72. Wiesenfeld-Hallin Z, Xu XJ, Hughes J, Horwell DC, Hökfelt T (1990) PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc Natl Acad Sci USA 87: 7105-7109
73. Willner P (1990) Animal models of depression: an overview. Pharmacol Ther 45:425-455
74. Wise RA (1983) Brain neuronal systems mediating reward processes. In: Smith JE, Lane JD (eds) Neurobiologie of opiate reward processes. Elsevier, Amsterdam, pp 405-437
75. Zhou Y, Sun YH, Zhang ZW, Han JS (1992) Accelerated expression of cholecystokinin gene in the brain of rats rendered tolerant to morphine. Neuroreport 3:1121-1124
76. Zimmerman M (1983) Guest editorial. Pain 16:109-110
77. Zuzel KA, Rose C, Schwartz JC (1985) Assessment of the role of enkephalinase in cholecystokinin inactivation. Neuroscience 15: 149-158